Brian Daniel Webster Sells 13,017 Shares of Kestra Medical Technologies (NASDAQ:KMTS) Stock

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) insider Brian Daniel Webster sold 13,017 shares of the business’s stock in a transaction on Monday, August 3rd. The shares were sold at an average price of $23.92, for a total value of $311,366.64. Following the transaction, the insider owned 527,115 shares of the company’s stock, valued at approximately $12,608,590.80. The trade was a 2.41% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Brian Daniel Webster also recently made the following trade(s):

• On Friday, July 31st, Brian Daniel Webster sold 8,948 shares of Kestra Medical Technologies stock. The shares were sold at an average price of $22.60, for a total value of $202,224.80.
• On Thursday, July 30th, Brian Daniel Webster sold 7,857 shares of Kestra Medical Technologies stock. The stock was sold at an average price of $22.72, for a total value of $178,511.04.
• On Monday, June 15th, Brian Daniel Webster sold 15,000 shares of Kestra Medical Technologies stock. The shares were sold at an average price of $20.81, for a total value of $312,150.00.
• On Friday, May 15th, Brian Daniel Webster sold 15,000 shares of Kestra Medical Technologies stock. The stock was sold at an average price of $20.96, for a total value of $314,400.00.

Kestra Medical Technologies Price Performance

KMTS opened at $25.93 on Wednesday. The company has a market capitalization of $1.52 billion, a price-to-earnings ratio of -10.71 and a beta of 0.58. The company has a current ratio of 4.41, a quick ratio of 4.41 and a debt-to-equity ratio of 0.16. Kestra Medical Technologies, Ltd. has a 12-month low of $14.10 and a 12-month high of $30.00. The business’s fifty day simple moving average is $22.70 and its 200-day simple moving average is $22.51.

Kestra Medical Technologies (NASDAQ:KMTS) last released its quarterly earnings data on Tuesday, July 14th. The company reported ($0.67) earnings per share for the quarter, missing the consensus estimate of ($0.59) by ($0.08). Kestra Medical Technologies had a negative net margin of 138.35% and a negative return on equity of 57.38%. The firm had revenue of $28.64 million during the quarter. On average, equities research analysts anticipate that Kestra Medical Technologies, Ltd. will post -2.29 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Kestra Medical Technologies

Several hedge funds have recently modified their holdings of KMTS. Farther Finance Advisors LLC purchased a new position in shares of Kestra Medical Technologies in the 4th quarter valued at about $31,000. Russell Investments Group Ltd. boosted its position in Kestra Medical Technologies by 43.5% during the fourth quarter. Russell Investments Group Ltd. now owns 1,563 shares of the company’s stock worth $41,000 after purchasing an additional 474 shares in the last quarter. Daiwa Securities Group Inc. acquired a new stake in Kestra Medical Technologies in the fourth quarter valued at approximately $72,000. BNP Paribas Financial Markets increased its position in shares of Kestra Medical Technologies by 148.9% in the third quarter. BNP Paribas Financial Markets now owns 2,738 shares of the company’s stock valued at $65,000 after buying an additional 1,638 shares in the last quarter. Finally, Brown Brothers Harriman & Co. raised its stake in shares of Kestra Medical Technologies by 26.8% during the 3rd quarter. Brown Brothers Harriman & Co. now owns 3,104 shares of the company’s stock worth $74,000 after buying an additional 656 shares during the period.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on KMTS shares. Wolfe Research set a $30.00 price objective on shares of Kestra Medical Technologies in a report on Wednesday, July 15th. Weiss Ratings cut Kestra Medical Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, July 16th. Oppenheimer began coverage on Kestra Medical Technologies in a research report on Tuesday, July 21st. They issued a “market perform” rating for the company. Wall Street Zen cut Kestra Medical Technologies from a “hold” rating to a “sell” rating in a research note on Saturday, July 18th. Finally, The Goldman Sachs Group dropped their price objective on Kestra Medical Technologies from $22.00 to $17.00 and set a “neutral” rating on the stock in a research report on Thursday, April 9th. Three investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Kestra Medical Technologies currently has an average rating of “Hold” and an average target price of $27.83.

Kestra Medical Technologies News Summary

Here are the key news stories impacting Kestra Medical Technologies this week:

• Positive Sentiment: Analyst sentiment remains mixed but includes three Buy ratings, with a consensus price target of $27.83. BTIG Research raised its target to $32 and maintained a Buy rating, while Wolfe Research set a $30 objective. Kestra Medical Technologies insider-selling report
• Positive Sentiment: Several institutional investors increased their positions, including Russell Investments Group, Brown Brothers Harriman, Rhumbline Advisers and New Jersey’s Police & Firemen’s Retirement System. These additions provide some support for institutional interest in KMTS.
• Neutral Sentiment: Executives and insiders sold roughly 103,000 shares worth more than $2.2 million between July 30 and August 3. Sellers included CFO Vaseem Mahboob and insiders Brian Daniel Webster, Traci S. Umberger, Alfred J. Ford Jr. and Timothy P. Moran. Because the filings specify tax-related sales, the transactions may reflect equity vesting rather than discretionary selling.
• Negative Sentiment: The number of sellers, including the CFO, could still weigh on investor sentiment and raise concerns about management ownership. Kestra’s latest quarterly loss of $0.67 per share exceeded the expected loss of $0.59, while revenue was $28.64 million and the company remains unprofitable.

About Kestra Medical Technologies

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.